CONTEMPORARY RECOMMENDATIONS ON PATIENT BLOOD MANAGEMENT IN JOINT ARTHROPLASTY

Acta Clin Croat. 2022 Sep;61(Suppl 2):78-83. doi: 10.20471/acc.2022.61.s2.09.

Abstract

Hip and knee replacement surgery are a common and effective procedure for the relief of pain and loss of function. The number of procedures is increasing and great interest is given how to improve outcome following hip and knee replacement surgery. Last two decades have been characterized by many innovations in hip and knee replacement surgery including minimally invasive technique but also by improvements in anesthetic technique and blood management. The patients undergoing hip and knee replacement surgery are commonly elderly and have cos-existing organ dysfunctions. These procedures are characterized by great perioperative disturbances including cardiovascular complications, high incidence of thromboembolic complications, possible significant perioperative blood loss, possible bone cement effect and high level of postoperative pain. Anesthetic assessment of patients include preoperative preparations, intraoperative and postoperative care. In this article, all problems of perioperative blood management are discussed. The recent data of advantages of blood management for every patient are outlined. Blood management include preoperative preparation, use of autologous blood in perioperative period and administration of drugs for minimizing intraoperative blood loss. The final result of improvements in blood management is reducing in blood loss and need for allogeneic blood and significant reduction in perioperative morbidity.

Keywords: autologous blood; blood management; joint replacement surgery; tranexamic acid.

Publication types

  • Review

MeSH terms

  • Aged
  • Antifibrinolytic Agents*
  • Arthroplasty, Replacement, Hip* / adverse effects
  • Arthroplasty, Replacement, Hip* / methods
  • Arthroplasty, Replacement, Knee* / adverse effects
  • Blood Loss, Surgical / prevention & control
  • Blood Transfusion
  • Humans
  • Tranexamic Acid*

Substances

  • Tranexamic Acid
  • Antifibrinolytic Agents